Patented Medicine Prices Review Board Canada
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the latest edition of the Market Intelligence Report: Antidiabetic Drugs, 2012-2021, which examines the market for drugs used in the treatment of diabetes.
This fourth report in the Market Intelligence series analyzes the market for drugs used in the treatment of diabetes. It is estimated that 5.7 million Canadians have diagnosed and undiagnosed diabetes, and another 6 million Canadians are likely prediabetic. The cost burden of diabetes in Canada is around $29 billion annually.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
